Therapeutic viruses have huge potential yet cannot currently be delivered intravenously, being limited to intratumoral injection. This restricts their clinical use.

Stratosvir Limited are developing a pioneering platform which is designed to relieve this crucial barrier that prevents systemic delivery. This allows their cancer-killing virus to deliver medicinal payloads within the tumour to stimulate and reprogram the immune system to attack and destroy cancer.